文献速递头颈与中枢神经肿瘤

DNMT3A改变在中东甲状腺乳头状癌中的预后意义

Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
PubMed 文献 · Eur J Cancer · 2019-07-04

该研究在超过1000例中东甲状腺乳头状癌(PTC)队列中评估DNMT3A改变频率,发现致病突变占1.2%(12/1013),表达降低/缺失占59.8%(579/968),且与侵袭性临床参数和不良预后相关;启动子甲基化占57.1%,去甲基化可恢复表达并增强TRAIL介导的凋亡。

要点

  • DNMT3A致病突变见于1.2%(12/1013)的PTC病例。
  • DNMT3A表达降低/缺失见于59.8%(579/968),与突变显著相关(p=0.0120)。
  • DNMT3A改变与侵袭性参数和不良预后相关,去甲基化可恢复其表达。

核心结论

  • DNMT3A改变在PTC发病中起重要作用,去甲基化药物可在部分患者中恢复DNMT3A功能。

研究设计与样本

  • 在超过1000例PTC队列中,采用外显子测序、捕获测序、免疫组化和甲基化特异性PCR评估DNMT3A改变,并进行体外细胞系分析。

主要发现

  • DNMT3A致病突变占1.2%(12/1013),表达降低/缺失占59.8%(579/968),突变与表达降低/缺失显著相关(p=0.0120)。
  • DNMT3A改变(突变和/或表达缺失)与侵袭性临床参数和不良结局相关。
  • DNMT3A启动子区在57.1%的受检PTC病例中甲基化,与DNMT3A蛋白表达降低显著相关(p=0.0253)。
  • 用5-aza-2'-脱氧胞苷处理甲基化的PTC细胞系可导致DNMT3A基因去甲基化并恢复其表达,去甲基化显著增强TRAIL介导的凋亡,而siRNA沉默DNMT3A抑制TRAIL介导的凋亡。

临床怎么用

  • DNMT3A改变(突变和/或表达缺失)与侵袭性临床参数和不良预后相关,可能作为PTC预后评估的参考指标。
  • 去甲基化药物可在部分PTC患者中恢复DNMT3A功能,并可能增强TRAIL介导的凋亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thyroid cancer is the second most common cancer affecting Saudi women after breast cancer, with papillary thyroid carcinoma (PTC) accounting for 80-90% of thyroid cancers. DNA methyltransferases affect DNA methylation, and it is thought that they play an important role in the malignant transformation of various cancers. METHODS: We sought to evaluate the frequency of DNA methyltransferase 3A (DNMT3A) alterations in a large cohort of >1000 PTC cases using exome sequencing, capture sequencing, immunohistochemistry and methylation-specific polymerase chain reaction. We also performed in vitro analysis to investigate the role of DNMT3A methylation in PTC cell lines. RESULTS: DNMT3A pathogenic mutations were noted in 1.2% (12/1013) of PTC cases. Reduced/loss of DNMT3A expression was seen in 59.8% (579/968) of PTC cases and was significantly associated with the DNMT3A mutation (p = 0.0120). DNMT3A alterations (mutation and/or loss of expression) were associated with aggressive clinical parameters and a poor outcome. The promoter region of the DNMT3A gene was methylated in 57.1% of PTC cases tested and was significantly associated with reduced DNMT3A protein expression (p = 0.0253). Treatment of the methylated PTC cell line with 5-aza-2'-deoxycytidine resulted in demethylation of the DNMT3A gene, leading to restoration of its expression. Demethylation significantly potentiated the TRAIL-mediated apoptosis in PTC cells. Interestingly, silencing of DNMT3A using siRNA suppressed TRAIL-mediated apoptosis. CONCLUSION: These findings suggest that DNMT3A alterations play an important role in PTC pathogenesis and demethylation agents can be used to restore the function of DNMT3A in a subset of patients with PTC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Siraj AK, Pratheeshkumar P, Parvathareddy SK, et al. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma. Eur J Cancer. 2019. PMID: 31280122. doi:10.1016/j.ejca.2019.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。